Achilles Therapeutics plc (ACHL)
Market Cap | 559.77M |
Revenue (ttm) | n/a |
Net Income (ttm) | -33.20M |
Shares Out | 40.62M |
EPS (ttm) | -0.82 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Dividend Yield | n/a |
Trading Day | April 9 |
Last Price | $13.78 |
Previous Close | $14.51 |
Change ($) | -0.73 |
Change (%) | -5.03% |
Day's Open | 14.28 |
Day's Range | 13.72 - 15.11 |
Day's Volume | 207,201 |
52-Week Range | 13.72 - 18.95 |
LONDON, April 06, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announc...
Achilles Therapeutics plc (NASDAQ: ACHL) announced the pricing of its IPO on the Nasdaq that will raise US$175.5mln (£127.8mln). The clinical-stage biopharma, which is developing precision T cell therap...
LONDON, March 30, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announc...
Achilles Therapeutics, a Phase 1/2 biotech developing precision T cell therapies for solid tumors, filed on Monday with the SEC to raise up to $100 million in an initial public offering.
Achilles Therapeutics plc has filed to go public with an IPO on the NASDAQ.
About ACHL
Achilles Therapeutics is a clinical stage immuno-oncology biopharmaceutical company developing precision T cell therapies to treat multiple types of solid tumors. Our platform enables us to identify mutations formed early in the development of a cancer that give rise to antigens. We refer to this novel class of solid tumor targets as clonal neoantigens. To identify clonal neoantigens in a patient, we have developed a proprietary bioinformatic platform called PELEUS. This platform employs sophisticated statistical algorithms trained on the uniqu... [Read more...]
Industry Biological Products | IPO Date Mar 31, 2021 |
CEO Iraj Ali, Ph.D. | Employees 153 |
Stock Exchange NASDAQ | Ticker Symbol ACHL |